ALFA Finder| Revenue growth | 27% YoY in Q1FY27 |
|---|---|
| Margins | EBITDA Margin at 34.7%; PAT Margin improved to 25.6%. |
| Demand visibility | Strong customer engagement and increasing visibility on battery material off-take. |
| Management confidence | High; confident in sustainable long-term growth and expansion projects. |
Growth
Q1FY27 Revenue grew 27% YoY to ₹158.3 Cr; PAT rose 30% YoY to ₹40.6 Cr.
Outlook
Greenfield expansion and SAM Phase 1 on track for March 2027; total capacity targeted at 2,28,700 MT by FY30.
Risks
Challenging global environment, geopolitical uncertainties, supply chain disruptions, gas constraints, and elevated logistics costs.
Last quarter's promises, checked
Delivered
- Guided 25,000 MT Phase 1 SAM commissioning by April 2027 → On track for March 2027 (= BEAT)
- Guided 150-160 working capital days → delivered 154 days (= BEAT)
- Guided 10% revenue growth for Pharma/Food segment → delivered 10% (= BEAT)
Partly delivered
- Guided EBITDA margins returning to 37-38% → delivered 34.7% (= PARTIAL)
Investor Presentation filed with BSE, NSE: SUDEEPPHRM. Summary written with AI assistance from the document.
Sudeep Pharma Ltd: key numbers
- Share price
- ₹1,223.20
- Market cap
- ₹13,816 Cr
- Revenue (annual)
- ₹642.3 Cr
- Net profit (annual)
- ₹172.9 Cr
- P/E (TTM)
- 73.4×Sector 43.8×
- Promoter holding
- 76.15%+0.00% QoQ
- FII holding
- 2.93%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Sudeep Pharma Ltd
All →Sudeep Pharma Earnings Call Transcript: Key Takeaways
Sudeep Pharma delivered record quarterly revenue led by its Pharma Food Nutrition (PFN) segment, though specialty ingredients face short-term headwinds from the pause of a government rice program.
Sudeep Pharma Investor Presentation: Key Takeaways
Q2FY27 revenue Rs196.7cr (+21% YoY), record EBITDA Rs73.2cr (+32%, 37.2% margin), PAT Rs51.8cr (+11%). Battery-materials pivot and Nandesari FDA approval are the strategic highlights.
Sudeep Pharma Q2 FY27 Results: Net Profit ₹51.8 Cr, Up 10.7% YoY
Sudeep Pharma Ltd reported revenue from operations of ₹196.7 Cr (+20.9% YoY) and net profit of ₹51.8 Cr (+10.7% YoY) for Q2 FY27.
- Key figure
- Net profit ₹51.8 Cr · +10.7% YoY
Sudeep Pharma Capacity Expansion
Sudeep Pharma received FDA approval for its new 51,200 MT greenfield plant at Nandesari, Gujarat. Commercial operations are expected to commence in H2 FY27 following customer qualification.
- manufacturing capacity
- 51200 MT
Sudeep Pharma Board Meeting Date
Sudeep Pharma has scheduled its Board meeting for 28 October 2026 to approve Q1 and H1 FY27 financial results. No results or monetary figures are disclosed in this intimation.
Sudeep Pharma Other Announcement
The company submitted the mandatory compliance certificate under Regulation 74(5) for the quarter ended September 30, 2026.